demonstrated that bone marrow-derived mesenchymal stem cells inhibit thioacetamide-induced liver fibrosis progression by suppressing the TGF-β/Smad signaling pathway or directly inhibiting hepatic stellate cell proliferation through upregulation of Notch1 expression and downregulation of PI3K/AKT or Wnt/β-catenin pathways, thereby reducing liver fibrosis (26). Here, AKT1 is linked to Hepatic fibrosis.